Multiple Sclerosis

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (OnlineFirst PDF)
Right arrow All Versions of this Article:
1352458507088105v1
14/6/759    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Sternberg, Z
Right arrow Articles by Munschauer, F
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sternberg, Z
Right arrow Articles by Munschauer, F
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
First published on May 27, 2008, doi:10.1177/1352458507088105

Multiple Sclerosis 2008;14:759.

A more recent version of this article appeared on July 1, 2008

Article

Soluble receptor for advanced glycation end products in multiple sclerosis: A potential marker of disease severity

Z Sternberg1*, B Weinstock-Guttman1, D Hojnacki1, P Zamboni2, R Zivadinov1, K Chadha3, A Lieberman3, L Kazim4, A Drake1, P Rocco5, E Grazioli1, and F Munschauer1

1 Department of Neurology, Baird MS center, Jacobs Neurological Institute, Buffalo, NY, USA
2 Vascular Disease Center, University of Ferrara, Ferrara, Italy
3 Department of Molecular & Cellular Biology, Roswell Park Cancer Institute, Buffalo, NY, USA
4 Biopolymer Facility & Mass Spectrometry, Roswell Park Cancer Institute, Buffalo, NY, USA
5 Department of Social & Preventive Medicine, University of Buffalo, Buffalo, NY, USA

* To whom correspondence should be addressed.


  Abstract

Objectives

To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS).

Method

37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA).

Results

Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls (p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts (p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed (p = 0.012).

Conclusion

The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

Key Words: soluble receptor, inflammatory markers, cytokines, biomarker, advanced glycation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?